AdBio partners manages a diverse portfolio in multiple therapeutic areas including oncology, immunology, ophthalmology and rare diseases.
We support innovative therapeutics projects with the potential to deliver first- or best-in-class products with high unmet medical needs. Our goal is to build and grow sustainable life sciences startups to develop tomorrow’s innovation in healthcare.
Alderaan Biotechnology
Paris based company – France
Alderaan Biotechnology develops antibodies directed against immune cells for the treatment of cancers. The first program is dedicated to the development of IL2-sparing, CD25-specific antibodies allowing Regulatory T cells (Tregs) depletion in tumours. The second program is focused on NK cell modulation using antibodies specific for CD160-TM, a new NK cell activating receptor.
Alderaan Biotechnology’s website
AdBio partners contact: Geoffroy de Ribains
AndzonBio1
Paris based company – France
AndzonBio1 is the first thematic Pipeline Builder Company to emerge from the AndzonBio® initiative, dedicated to accelerating the most promising academic projects in cardiovascular, renal and metabolic (CVRM) disorders.
AdBio partners contact: Alain Huriez
Agomab Therapeutics
Agomab Therapeutics develops agonistic antibodies targeting the receptor c-MET that recapitulate the regenerative and anti-inflammatory properties of the ligand HGF.
AdBio partners contact: Alain Huriez
AndzonBio
Paris based company – France
AndzonBio is a suite of thematic Pipeline Builder Companies to accelerate the industrial development of the most promising academic projects in biotechnology.
AdBio partners contact: Alain Huriez
Arthex Biotech
Valence based company – Spain
ARTHEx Biotech develops antisense technologies targeting miR-23b and miR-218 for the treatment of Myotonic Dystrophy type 1 (DM1).
AdBio partners contact: Alain Huriez
Augustine Therapeutics
Leuven based company – Belgium
Augustine Therapeutics is developing new selective HDAC6 inhibitors for the treatment of neurological diseases such as Charcot Marie Tooth disease and peripheral neuropathies. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin repair.
Augustine Therapeutics’s website
AdBio partners contact: Alain Huriez
Depth Charge
Paris based company – France
Depth Charge Therapeutics develops novel immune oncology agents for tumour-selective modulation of the microenvironment.
AdBio partners contact: Geoffroy de Ribains
DiogenX
Marseille based company – France
DiogenX is developing new compounds for beta cells regeneration for the treatment of type-1 diabetes.
AdBio partners contact: Geoffroy de Ribains
Integra Therapeutics
Barcelona based company – Spain
Integra Therapeutics develops a proprietary gene editing platform for in vivo and ex vivo permanent gene editing.
Integra Therapeutics’s website
AdBio partners contact: Geoffroy de Ribains
Kalsiom
Brest based company – France
Kalsiom develops first-in-class antibodies targeting calcium signaling for the treatment of auto-immune diseases.
AdBio partners contact: Geoffroy de Ribains
Ribonexus
Paris based company – France
Ribonexus is developing small molecules targeting eif4F complex in cancer.
AdBio partners contact: Geoffroy de Ribains
SparingVision
SparingVision develops gene therapy treatments for patients affected by Inherited Retinal Diseases, regardless of genetic cause.
AdBio partners contact: Clément Bertholet
Thabor Therapeutics
Rennes based company – France
Thabor Therapeutics develops innovative treatments based on monoclonal antibodies for human mucosal inflammatory diseases.
Thabor Therapeutics’s linkedin
AdBio partners contact: Alain Huriez
Tridek-One
Tridek-One develops a first-in-class monoclonal antibody that maintains clusters of truncated CD31 to the membrane. This original approach has a high therapeutic potential for a diversity of auto-immune and inflammatory disorders.
AdBio partners contact: Clément Bertholet
Univercells
Global life sciences company offering best-in-class biomanufacturing infrastructure.
AdBio partners contact: Clément Bertholet
Urania Therapeutics
Urania Therapeutics is developing a unique structure-based drug discovery platform for the generation of new readthrough compounds to treat cancer and rare diseases.
AdBio partners contact: Geoffroy de Ribains
Yukin Therapeutics
Nice based company – France
Yukin Therapeutics develops small molecules that inhibit the non-canonical NF-κB2 pathway. These new compounds have the potential to inhibit cancer cell proliferation and to massively modulate the tumour micro-environment.
AdBio partners contact: Alain Huriez
Calida Therapeutics
Paris based company – France
Calida Therapeutics develops a first-in-class approach to address thrombo-inflammation and vascular diseases
AdBio partners contact: Alain Huriez
Astraveus
Paris based company – France
Astraveus is developing a proprietary enabling platform for Cell and Gene Therapy manufacturing, leveraging microfluidics, to transform patient access to life-changing therapies.
Orikine Bio
Orikine Bio is a pioneering biotech company dedicated to advancing the field of engineered cytokines with unparalleled biological features for the treatment of immune-mediated diseases.
AdBio partners contact: Clément Bertholet
Kiji Therapeutics
Paris based company
Kiji therapeutics is developing a new generation of IPSC-MSC engineered cell therapy for inflammatory diseases
AdBio partners contact: Alain Huriez
Anoat Therapeutics
Paris based company – France
Anoat Therapeutics develops an innovative, disease-modifying approach in Cystic Fibrosis.
AdBio partners contact: Alain Huriez
Tenpoint Therapeutics
Tenpoint Therapeutics is a clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
Tenpoint Therapeutics’s website
AdBio partners contact: Clément Bertholet